Phase II Trial of Combined Modality Therapy With Growth Factor Support in Locally Advanced NSCLC.

Trial Profile

Phase II Trial of Combined Modality Therapy With Growth Factor Support in Locally Advanced NSCLC.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Cisplatin; Docetaxel; Etoposide; Filgrastim; Pegfilgrastim
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Apr 2012 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 19 Apr 2012 Actual patient number is 26 according to ClinicalTrials.gov.
    • 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top